Enservco Corporation is a diversified service provider in the energy sector, specializing in water management, heating, and logistical solutions primarily for oil and natural gas exploration and production companies
The company offers a range of services, including frac water heating, hot oiling, and water sourcing and disposal, aimed at enhancing operational efficiency and compliance with environmental regulations. Enservco focuses on supporting its clients by delivering efficient and cost-effective services, utilizing advanced technology and equipment to meet the unique challenges of the energy industry.
Shares of Macatawa Bank Corporation (NASDAQMCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corporation NASDAQ: WFTCNASDAQWFTC)
Companies Reporting Before The Bell • Mach Natural Resources (NYSEMNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enservco Corporation (NYSEENSV) on behalf of long-term stockholders following a class action complaint that was filed against Enservco on May 20, 2022 with a Class Period from March 23, 2021 to September 1, 2022. Our investigation concerns whether the board of directors of Enservco have breached their fiduciary duties to the company.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enservco Corp. (NYSEENSV) on behalf of long-term stockholders following a class action complaint that was filed against Enservco on May 20, 2022 with a Class Period from May 13, 2021 to April 18, 2022. Our investigation concerns whether the board of directors of Enservco have breached their fiduciary duties to the company.
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQSONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.
Gainers Vaxcyte, Inc. (NASDAQPCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24.
